3 Stocks Estimated To Be Up To 39% Below Their Intrinsic Value
In This Article:
As global markets navigate the challenges posed by rising U.S. Treasury yields and tepid economic growth, investors are increasingly focused on identifying opportunities within a fluctuating landscape. Amid these conditions, stocks that are estimated to be trading below their intrinsic value offer potential for those looking to capitalize on market inefficiencies.
Top 10 Undervalued Stocks Based On Cash Flows
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Lindab International (OM:LIAB) | SEK227.40 | SEK453.69 | 49.9% |
| California Resources (NYSE:CRC) | US$52.09 | US$104.09 | 50% |
| Geovis TechnologyLtd (SHSE:688568) | CN￥40.77 | CN￥81.12 | 49.7% |
| Grupo Traxión. de (BMV:TRAXION A) | MX$21.46 | MX$42.66 | 49.7% |
| Super Group (JSE:SPG) | ZAR23.21 | ZAR46.16 | 49.7% |
| WEX (NYSE:WEX) | US$173.16 | US$346.09 | 50% |
| Foxtons Group (LSE:FOXT) | ￡0.594 | ￡1.19 | 49.9% |
| SBI Sumishin Net Bank (TSE:7163) | ￥2725.00 | ￥5408.67 | 49.6% |
| DPC Dash (SEHK:1405) | HK$65.00 | HK$129.82 | 49.9% |
| Sinch (OM:SINCH) | SEK31.33 | SEK62.49 | 49.9% |
Let's uncover some gems from our specialized screener.
Vimian Group
Overview: Vimian Group AB (publ) operates in the global animal health industry and has a market cap of SEK23.70 billion.
Operations: The company's revenue is derived from four main segments: Medtech (€112.75 million), Diagnostics (€20.32 million), Specialty Pharma (€163.45 million), and Veterinary Services (€56.11 million).
Estimated Discount To Fair Value: 19.1%
Vimian Group is trading at SEK45.3, below its estimated fair value of SEK55.97, suggesting it may be undervalued based on cash flows. Despite recent net losses in Q3 2024, the company has shown strong revenue growth and forecasts significant earnings growth of 94.1% annually over the next three years, outpacing the Swedish market's 15.8%. However, past shareholder dilution and low future return on equity (9.1%) are potential concerns for investors.
-
Our growth report here indicates Vimian Group may be poised for an improving outlook.
-
Delve into the full analysis health report here for a deeper understanding of Vimian Group.
Kotobuki Spirits
Overview: Kotobuki Spirits Co., Ltd. is a Japanese company that produces and sells sweets, with a market capitalization of approximately ￥319.07 billion.
Operations: The company's revenue segments include Shukrei at ￥27.03 billion, Casey Shii at ￥18.88 billion, Kujukushima at ￥6.56 billion, Sales Subsidiaries at ￥7.06 billion, and Kotobuki Confectionery/Tajima Kotobuki at ￥13.19 billion.
Estimated Discount To Fair Value: 39%
Kotobuki Spirits, trading at ￥2095.5, is significantly undervalued with a fair value estimate of ￥3434.73. The company's earnings grew by 33.7% last year and are forecast to grow 12.8% annually, surpassing the JP market's growth rate of 8.7%. Despite revenue growth being slower than 20% per year, its projected return on equity is robust at 28.1%, making it an attractive proposition for investors focused on cash flow valuation metrics.